Home  
  Our Team  
  Patient Info  
  Services  
   
  Pay My Bill  
  Contact Us  

News for Healthier Living

ASCO 2026: Sylvester Trial Tests Virus-Immunotherapy Combination for Neuroendocrine Tumors

ASCO - Researchers from Sylvester Comprehensive Cancer Center will present phase 1 trial findings testing whether the tumor-targeting virus SVV-001 can improve immunotherapy in aggressive high-grade neuroendocrine tumors. The first three dose levels showed no severe treatment-related side effects.

May 21, 2026


June 3 2026

June 2 2026

June 1 2026

May 31 2026

May 30 2026

May 29 2026

May 28 2026

May 27 2026

May 26 2026

May 25 2026

May 22 2026

May 21 2026